Not Enough Room in This Town for Both ENDP and WPI

Slow down a minute Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) - there’s already a generic Lipoderm skin patch like the one you just submitted an NDA (new drug application for). At least that’s the story from Watson Laboratories Inc. (NYSE: WPI), which recently notified Endo Pharmaceuticals Holdings of the overlap.

Watson Laboratories Inc. invoked a ‘paragraph IV’ clause to let regulators – and Endo – know it has already filed for a copycat version of the same generic version of Endo’s post-shingles treatment that Endo even more recently applied for. Though not necessarily a final decision, ENDP shares are down 3% on the news.